Beam Therapeutics launched BEAM‑304, a liver‑targeted base‑editing program designed to correct common PAH mutations that cause phenylketonuria (PKU), and signaled intent to file an IND in 2026. The company described a multi‑editor strategy to address the prevalent R408W mutation and reported preclinical normalization of plasma phenylalanine in mouse models. Beam plans a Phase I/II trial to assess safety and Phe reduction. Separately, Pfizer moved to secure global rights to a liver‑targeted gene editing candidate previously held by another developer, locking in control of an in‑liver editing program as big pharmas shore up gene‑editing portfolios. Beam’s program and Pfizer’s licensing activity underscore continued industry commitment to one‑time genetic therapies for inherited metabolic disorders. Beam also finalized strategic financing to support its broader liver editing efforts and potential downstream launches.